Twist Bioscience Reports First Quarter Fiscal 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Twist Bioscience Corporation (TWST) Misses Q1 EPS by 86c, Revenues Beat; Offers FY20 Revenue Mid-Point Guidance Below Consensus
February 6, 2020 4:45 PM ESTTwist Bioscience Corporation (NASDAQ: TWST) reported Q1 EPS of ($1.69), $0.86 worse than the analyst estimate of ($0.83). Revenue for the quarter came in at $17.16 million versus the consensus estimate of $16.07 million.
FISCAL 2020 FIRST QUARTER FINANCIAL RESULTS
Orders: Total orders received for the first quarter of fiscal 2020 were $24.8 million, compared to $15.2 million for the same period of fiscal 2019.Revenue: Total revenues were $17.2 million for the first quarter of fiscal 2020 compared to $11.5 million for the same period of fiscal 2019.Cost of Revenues: Cost of revenues for the first quarter of fiscal 2020 was $13.8 million... More